CASE STUDY
The rosalind study
Decoding exceptional Cancer Survivors’ biology to reshape the future of Cancer care.
WHAT WE DO
Identifying a global biological signature associated with patients with unexpected survival, in order to develop new therapeutic strategies.
1
In each cohort, we identify and analyze a global signature associated with patients with unexpected survival (cases) compared to patients with standard survival (controls)
2
We identify potential new therapeutic strategies based on the findings from the case/control analysis
3
We aim to discover the biological differences that enable exceptional survival and translate them into actionable therapeutic targets that can benefit all patients.
A GLOBAL SCIENTIFIC COLLABORATION
The Rosalind Study unites a solid network of 50+ leading oncology centers in 40+ countries across 5 continents.
OUR VISION
By revealing how some patients overcome the most aggressive Cancers, we can inspire the next generation of therapies and offer new hope to millions of patients worldwide.
The Rosalind Study represents the largest collaborative scientific effort to understand exceptional Cancer survival.
A MultiOmics Strategy
All samples will be collected at the Cure51 Central Lab for molecular profiling.
Spatial transcriptomics
(10X Genomics Xenium/Visium)
Single-cell transcriptomics
(10X Genomics Flex)
Whole Exome Sequencing
Microbiomics (16s RNA)
Proteomics
(FFPE mass-spectrometry)
METHODOLOGY
This is a fully retrospective, exploratory, multi-center, translational, 3 cohorts case control (1:1) matched study conducted in patients harboring a solid tumor with poor prognosis (less than 10% 5-years overall survival) who presented a long-term (case) and standard survival (control).
Metastatic pancreatic ductal adenocarcinoma
Glioblastoma IDHwt (WHO 2021 classification)
Extensive small cell lung cancer
conclusion
Rosalind is the first study building a clinical and multiomics database of Outliers at an international scale with an expected sample size of 500+ survivors and with depth molecular characterization including single cell and spatial modalities.
This allows us to expand the range of signatures and targets at a level that no academic initiative could reach. We will focus on any down regulated protein or dysregulated pathway specific to Outliers that is otherwise overly expressed in control patients as a target for therapeutic development.
Actionability of Outlier biology is based on the possibility to target almost anything in current biochemistry R&D - the key in bringing a treatment to the market being the identification of the RIGHT target with functional effects and no toxicity.
